Cargando…
Comparative Assessment of p16/Ki-67 Dual Staining Technology for cervical cancer screening in women living with HIV (COMPASS-DUST)–Study protocol
The risk of progression of low-grade (CIN1) to high-grade cervical intraepithelial neoplasia (CIN2/3) is 3–5 times higher for women living with HIV (WLHIV) than for HIV-negative women. Evidence suggests that the current cervical cancer screening methods perform less effectively in WLHIV. An emerging...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9879465/ https://www.ncbi.nlm.nih.gov/pubmed/36701329 http://dx.doi.org/10.1371/journal.pone.0278077 |
_version_ | 1784878695393001472 |
---|---|
author | Okunade, Kehinde S. Badmos, Kabir B. Okoro, Austin C. Ademuyiwa, Iyabo Y. Oshodi, Yusuf A. Adejimi, Adebola A. Awolola, Nicholas A. Ozonu, Oluchi Adelabu, Hameed Olorunfemi, Gbenga Akanmu, Alani S. Banjo, Adekunbiola A. Anorlu, Rose I. Berek, Jonathan S. |
author_facet | Okunade, Kehinde S. Badmos, Kabir B. Okoro, Austin C. Ademuyiwa, Iyabo Y. Oshodi, Yusuf A. Adejimi, Adebola A. Awolola, Nicholas A. Ozonu, Oluchi Adelabu, Hameed Olorunfemi, Gbenga Akanmu, Alani S. Banjo, Adekunbiola A. Anorlu, Rose I. Berek, Jonathan S. |
author_sort | Okunade, Kehinde S. |
collection | PubMed |
description | The risk of progression of low-grade (CIN1) to high-grade cervical intraepithelial neoplasia (CIN2/3) is 3–5 times higher for women living with HIV (WLHIV) than for HIV-negative women. Evidence suggests that the current cervical cancer screening methods perform less effectively in WLHIV. An emerging screening method–p16/Ki-67 dual staining technology (DUST) is a safe and rapid assay that could be used to detect CIN2/3 with higher sensitivity and specificity. The study in this protocol will evaluate the performance of DUST in cervical cancer screening among WLHIV. We will conduct an intra-participant comparative study (Phase 1) to enrol n = 1,123 sexually active WLHIV aged 25–65 years at two accredited adult HIV treatment centres in Lagos, Nigeria to compare the performance of DUST to the currently used screening methods (Pap smear, hr-HPV DNA, or VIA testing) in detecting high-grade CIN and cancer (CIN2+). Subsequently, a prospective cohort study (Phase 2) will be conducted by enrolling all the WLHIV who are diagnosed as having low-grade CIN (CIN1) in Phase 1 for a 6-monthly follow-up for 2 years to detect the persistence and progression of CIN1 to CIN2+. The findings of this study may provide evidence of the existence of a better performance screening method for the primary and triage detection of CIN2+ in WLHIV. It may also demonstrate that this high-performance test can improve the long-term predictive accuracy of screening by extending the intervals between evaluations and thus decrease the overall cost and increase screening uptake and follow-up compliance in WLHIV. |
format | Online Article Text |
id | pubmed-9879465 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-98794652023-01-27 Comparative Assessment of p16/Ki-67 Dual Staining Technology for cervical cancer screening in women living with HIV (COMPASS-DUST)–Study protocol Okunade, Kehinde S. Badmos, Kabir B. Okoro, Austin C. Ademuyiwa, Iyabo Y. Oshodi, Yusuf A. Adejimi, Adebola A. Awolola, Nicholas A. Ozonu, Oluchi Adelabu, Hameed Olorunfemi, Gbenga Akanmu, Alani S. Banjo, Adekunbiola A. Anorlu, Rose I. Berek, Jonathan S. PLoS One Study Protocol The risk of progression of low-grade (CIN1) to high-grade cervical intraepithelial neoplasia (CIN2/3) is 3–5 times higher for women living with HIV (WLHIV) than for HIV-negative women. Evidence suggests that the current cervical cancer screening methods perform less effectively in WLHIV. An emerging screening method–p16/Ki-67 dual staining technology (DUST) is a safe and rapid assay that could be used to detect CIN2/3 with higher sensitivity and specificity. The study in this protocol will evaluate the performance of DUST in cervical cancer screening among WLHIV. We will conduct an intra-participant comparative study (Phase 1) to enrol n = 1,123 sexually active WLHIV aged 25–65 years at two accredited adult HIV treatment centres in Lagos, Nigeria to compare the performance of DUST to the currently used screening methods (Pap smear, hr-HPV DNA, or VIA testing) in detecting high-grade CIN and cancer (CIN2+). Subsequently, a prospective cohort study (Phase 2) will be conducted by enrolling all the WLHIV who are diagnosed as having low-grade CIN (CIN1) in Phase 1 for a 6-monthly follow-up for 2 years to detect the persistence and progression of CIN1 to CIN2+. The findings of this study may provide evidence of the existence of a better performance screening method for the primary and triage detection of CIN2+ in WLHIV. It may also demonstrate that this high-performance test can improve the long-term predictive accuracy of screening by extending the intervals between evaluations and thus decrease the overall cost and increase screening uptake and follow-up compliance in WLHIV. Public Library of Science 2023-01-26 /pmc/articles/PMC9879465/ /pubmed/36701329 http://dx.doi.org/10.1371/journal.pone.0278077 Text en © 2023 Okunade et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Study Protocol Okunade, Kehinde S. Badmos, Kabir B. Okoro, Austin C. Ademuyiwa, Iyabo Y. Oshodi, Yusuf A. Adejimi, Adebola A. Awolola, Nicholas A. Ozonu, Oluchi Adelabu, Hameed Olorunfemi, Gbenga Akanmu, Alani S. Banjo, Adekunbiola A. Anorlu, Rose I. Berek, Jonathan S. Comparative Assessment of p16/Ki-67 Dual Staining Technology for cervical cancer screening in women living with HIV (COMPASS-DUST)–Study protocol |
title | Comparative Assessment of p16/Ki-67 Dual Staining Technology for cervical cancer screening in women living with HIV (COMPASS-DUST)–Study protocol |
title_full | Comparative Assessment of p16/Ki-67 Dual Staining Technology for cervical cancer screening in women living with HIV (COMPASS-DUST)–Study protocol |
title_fullStr | Comparative Assessment of p16/Ki-67 Dual Staining Technology for cervical cancer screening in women living with HIV (COMPASS-DUST)–Study protocol |
title_full_unstemmed | Comparative Assessment of p16/Ki-67 Dual Staining Technology for cervical cancer screening in women living with HIV (COMPASS-DUST)–Study protocol |
title_short | Comparative Assessment of p16/Ki-67 Dual Staining Technology for cervical cancer screening in women living with HIV (COMPASS-DUST)–Study protocol |
title_sort | comparative assessment of p16/ki-67 dual staining technology for cervical cancer screening in women living with hiv (compass-dust)–study protocol |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9879465/ https://www.ncbi.nlm.nih.gov/pubmed/36701329 http://dx.doi.org/10.1371/journal.pone.0278077 |
work_keys_str_mv | AT okunadekehindes comparativeassessmentofp16ki67dualstainingtechnologyforcervicalcancerscreeninginwomenlivingwithhivcompassduststudyprotocol AT badmoskabirb comparativeassessmentofp16ki67dualstainingtechnologyforcervicalcancerscreeninginwomenlivingwithhivcompassduststudyprotocol AT okoroaustinc comparativeassessmentofp16ki67dualstainingtechnologyforcervicalcancerscreeninginwomenlivingwithhivcompassduststudyprotocol AT ademuyiwaiyaboy comparativeassessmentofp16ki67dualstainingtechnologyforcervicalcancerscreeninginwomenlivingwithhivcompassduststudyprotocol AT oshodiyusufa comparativeassessmentofp16ki67dualstainingtechnologyforcervicalcancerscreeninginwomenlivingwithhivcompassduststudyprotocol AT adejimiadebolaa comparativeassessmentofp16ki67dualstainingtechnologyforcervicalcancerscreeninginwomenlivingwithhivcompassduststudyprotocol AT awololanicholasa comparativeassessmentofp16ki67dualstainingtechnologyforcervicalcancerscreeninginwomenlivingwithhivcompassduststudyprotocol AT ozonuoluchi comparativeassessmentofp16ki67dualstainingtechnologyforcervicalcancerscreeninginwomenlivingwithhivcompassduststudyprotocol AT adelabuhameed comparativeassessmentofp16ki67dualstainingtechnologyforcervicalcancerscreeninginwomenlivingwithhivcompassduststudyprotocol AT olorunfemigbenga comparativeassessmentofp16ki67dualstainingtechnologyforcervicalcancerscreeninginwomenlivingwithhivcompassduststudyprotocol AT akanmualanis comparativeassessmentofp16ki67dualstainingtechnologyforcervicalcancerscreeninginwomenlivingwithhivcompassduststudyprotocol AT banjoadekunbiolaa comparativeassessmentofp16ki67dualstainingtechnologyforcervicalcancerscreeninginwomenlivingwithhivcompassduststudyprotocol AT anorlurosei comparativeassessmentofp16ki67dualstainingtechnologyforcervicalcancerscreeninginwomenlivingwithhivcompassduststudyprotocol AT berekjonathans comparativeassessmentofp16ki67dualstainingtechnologyforcervicalcancerscreeninginwomenlivingwithhivcompassduststudyprotocol |